Noxopharm Ltd.

As of June 30, 2024, Noxopharm Ltd. carries a market capitalization of 19.29M, placing it among publicly traded companies globally. Its enterprise value stands at 16.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Noxopharm Ltd. has 292.24M shares outstanding.

These figures are as of June 30, 2024.

As of June 30, 2024, Noxopharm Ltd. maintains a current ratio of 3.83, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Noxopharm Ltd. posted a negative return on equity (ROE) of -49.12, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -42.31, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Noxopharm Ltd.'s stock has declined approximately 44.44% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.

These figures cover the twelve months ended June 30, 2024. EBITDA reached -7.00M, while operating income came in at -7.00M.

These figures are as of June 30, 2024. Total book value stands at 5.50M, with working capital of 3.52M providing operational flexibility.

Noxopharm Ltd.'s most recent stock split took place on May 19, 2020 with a 68:77 split ratio.